GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Vanda Pharmaceuticals Inc. (VNDA) [hlAlert]

Rating:
Neutral VNDA

Vanda Pharmaceuticals Inc. (VNDA) rated Neutral by JP Morgan

Posted on: Tuesday,  Jul 29, 2008  8:25 AM ET by JP Morgan

Vanda Pharma (VNDA)
rated Neutral by JP Morgan.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/29/2008 8:25 AM Hold
None
0.91
as of 12/24/2008
1 Week down  -10.47 %
1 Month up  17.50 %
3 Months up  23.68 %
1 YTD up  88.00 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy